» Articles » PMID: 22761894

The Negative Feedback-loop Between the Oncomir Mir-24-1 and Menin Modulates the Men1 Tumorigenesis by Mimicking the "Knudson's Second Hit"

Overview
Journal PLoS One
Date 2012 Jul 5
PMID 22761894
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple endocrine neoplasia type 1 (MEN1) syndrome is a rare hereditary cancer disorder characterized by tumors of the parathyroids, of the neuroendocrine cells, of the gastro-entero-pancreatic tract, of the anterior pituitary, and by non-endocrine neoplasms and lesions. MEN1 gene, a tumor suppressor gene, encodes menin protein. Loss of heterozygosity at 11q13 is typical of MEN1 tumors, in agreement with the Knudson's two-hit hypothesis. In silico analysis with Target Scan, Miranda and Pictar-Vert softwares for the prediction of miRNA targets indicated miR-24-1 as capable to bind to the 3'UTR of MEN1 mRNA. We investigated this possibility by analysis of miR-24-1 expression profiles in parathyroid adenomatous tissues from MEN1 gene mutation carriers, in their sporadic non-MEN1 counterparts, and in normal parathyroid tissue. Interestingly, the MEN1 tumorigenesis seems to be under the control of a "negative feedback loop" between miR-24-1 and menin protein, that mimics the second hit of Knudson's hypothesis and that could buffer the effect of the stochastic factors that contribute to the onset and progression of this disease. Our data show an alternative way to MEN1 tumorigenesis and, probably, to the "two-hit dogma". The functional significance of this regulatory mechanism in MEN1 tumorigenesis is also the basis for opening future developments of RNA antagomir(s)-based strategies in the in vivo control of tumorigenesis in MEN1 carriers.

Citing Articles

Molecular Pathophysiology of Parathyroid Tumorigenesis-The Lesson from a Rare Disease: The "MEN1 Model".

Brunetti A, Cosso R, Vescini F, Falchetti A Int J Mol Sci. 2024; 25(21).

PMID: 39519139 PMC: 11545851. DOI: 10.3390/ijms252111586.


Childhood Multiple Endocrine Neoplasia (MEN) Syndromes: Genetics, Clinical Heterogeneity and Modifying Genes.

Lanzaro F, De Biasio D, Cesaro F, Stampone E, Tartaglione I, Casale M J Clin Med. 2024; 13(18).

PMID: 39336996 PMC: 11432259. DOI: 10.3390/jcm13185510.


Menin in Cancer.

Majer A, Hua X, Katona B Genes (Basel). 2024; 15(9).

PMID: 39336822 PMC: 11431421. DOI: 10.3390/genes15091231.


[Plasma miRNA expression in patients with genetically confirmed multiple endocrine neoplasia type 1 syndrome and its phenocopies].

Trukhina D, Mamedova E, Nikitin A, Koshkin P, Belaya Z, Melnichenko G Probl Endokrinol (Mosk). 2024; 69(6):70-85.

PMID: 38311997 PMC: 10848189. DOI: 10.14341/probl13357.


Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.

Saleh Z, Moccia M, Ladd Z, Joneja U, Li Y, Spitz F Int J Mol Sci. 2024; 25(2).

PMID: 38279330 PMC: 10816436. DOI: 10.3390/ijms25021331.


References
1.
Ciafre S, Galardi S, Mangiola A, Ferracin M, Liu C, Sabatino G . Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005; 334(4):1351-8. DOI: 10.1016/j.bbrc.2005.07.030. View

2.
Petrocca F, Visone R, Onelli M, Shah M, Nicoloso M, De Martino I . E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008; 13(3):272-86. DOI: 10.1016/j.ccr.2008.02.013. View

3.
Xu N, Papagiannakopoulos T, Pan G, Thomson J, Kosik K . MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009; 137(4):647-58. DOI: 10.1016/j.cell.2009.02.038. View

4.
Galasso M, Sana M, Volinia S . Non-coding RNAs: a key to future personalized molecular therapy?. Genome Med. 2010; 2(2):12. PMC: 2847703. DOI: 10.1186/gm133. View

5.
Knudson Jr A . Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68(4):820-3. PMC: 389051. DOI: 10.1073/pnas.68.4.820. View